Table 1 Baseline demographic and clinical data
From: Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
Full cohort | SD | ATII | SD | Placebo | SD | P-value1 | |
|---|---|---|---|---|---|---|---|
Age, years | 62.85 | 15.81 | 68.40 | 17.46 | 57.30 | 12.44 | 0.12 |
Male, number | 15 | NA | 6 | NA | 9 | NA | 0.30 |
Race, number | |||||||
Caucasian | 9 | NA | 6 | NA | 3 | NA | 0.37 |
Black | 8 | NA | 3 | NA | 5 | NA | 0.65 |
Other | 3 | NA | 1 | NA | 2 | NA | 1.00 |
Severity of illness | NA | NA | NA | ||||
Baseline SOFA score | 15.90 | 2.97 | 14.9 | 2.81 | 16.90 | 2.92 | 0.14 |
APACHE score | 30.60 | 8.86 | 27.2 | 9.67 | 34.00 | 6.83 | 0.09 |
Past medical history, number | |||||||
IHD | 2 | NA | 1 | NA | 1 | NA | 1.00 |
CHF | 2 | NA | 2 | NA | 0 | NA | 0.47 |
COPD | 2 | NA | 2 | NA | 0 | NA | 0.47 |
DM | 7 | NA | 4 | NA | 3 | NA | 1.00 |
CKD | 7 | NA | 3 | NA | 4 | NA | 1.00 |
HD | 1 | NA | 0 | NA | 1 | NA | 1.00 |
Liver disease | 9 | NA | 5 | NA | 4 | NA | 1.00 |
Cancer | 6 | NA | 1 | NA | 5 | NA | 0.14 |
IS | 6 | NA | 1 | NA | 5 | NA | 0.14 |
Steroids | 3 | NA | 1 | NA | 2 | NA | 1.00 |
Hypertension | 9 | NA | 4 | NA | 5 | NA | 1.00 |
CVA | 5 | NA | 4 | NA | 1 | NA | 0.30 |
AKI | 17 | NA | 9 | NA | 8 | NA | 1.00 |
Laboratory measurements mean | |||||||
White blood cells | 17.38 | NA | 19.0 | 16.0 | 15.72 | 12.3 | 0.61 |
Hgb | 9.45 | NA | 9.16 | 2.14 | 9.73 | 2.45 | 0.59 |
Creatinine | 2.33 | NA | 1.89 | 1.03 | 2.76 | 1.34 | 0.12 |
pH | 7.33 | NA | 7.34 | 0.11 | 7.32 | 0.12 | 0.63 |
Lactate | 5.83 | NA | 4.59 | 3.11 | 7.06 | 5.16 | 0.21 |
Baseline vasopressor doses2 | |||||||
Norepinephrine | 25.05 | 17.03 | 19.80 | 11.67 | 30.30 | 20.37 | 0.18 |
Vasopressin | 0.04 | 0.02 | 0.03 | 0.02 | 0.05 | 0.02 | 0.10 |